Emerging Nanomedicines for Diabetes Mellitus Theranostics

Dr. Danquah is a full Professor and the Director of Chemical Engineering Program at the University of Tennessee, Chattanooga, United States. He is a Chartered Engineer (CEng), Chartered Professional Engineer (CPEng), Chartered Scientist (CSci) and a Fellow of the Institution of Chemical Engineers (IChemE). Dr. Danquah’s research focuses on the utilization of bioprocess and biomolecular engineering principles to develop emerging biopharmaceuticals, biosensing and molecular separation systems; environmental bioremediation systems; and biofuels and bio-products. Dr. Danquah’s research findings are well published and cited with over 230 peer-reviewed journal articles, book chapters, conference publications and technical reports. His research has also resulted in intellectual properties and patent applications, large-scale manufacturing plants, and commercialized products and formulations. Dr. Jaison Jeevanandam is a Senior Researcher at the National Institute of Mental Health (NUDZ) in the Czech Republic. He earned his Ph.D. in Chemical Engineering from the Faculty of Engineering and Science at Curtin University, Malaysia. He has extensive experience in nanoparticle synthesis, particularly green synthesis using plant extracts, as well as nanoparticle characterization, cytotoxicity analysis, and in vitro diabetic models. His current research focuses on the application of nanobiotechnology in the development of nanoformulations for drug delivery systems.

• 1. The current state of diabetes treatment2. Nanoparticles and nanocomposites for controlled delivery of insulin3. Nanomaterials as glucose sensors for diabetes monitoring4. Nano-tattoos—a novel approach for glucose monitoring and diabetes management5. Metal and metal oxide nanoparticles: synthesis, properties, and applications as nanomedicines for diabetes treatment6. Biosynthesized nanoparticles for diabetes treatment7. Cytotoxicity of nanoparticles toward diabetic cell models8. In vivo studies of nanoparticles in diabetic models9. Preclinical and clinical evaluation of nanodrugs for diabetes treatment10. Future of nanoparticles, nanomaterials, and nanomedicines in diabetes treatment